Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that positive detailed one-year results from the Phase 3 PANORAMA trial evaluating EYLEA® ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis SymposiumFebruary 9, 2019 4:30 PM Regeneron Pharma (REGN) PT Raised to $421 at Morgan StanleyFebruary 8, 2019 7:34 AM Regeneron Pharma (REGN) PT Raised to $480 at OppenheimerFebruary 7, 2019 8:15 AM Regeneron Pharma (REGN) PT Raised to $412 at BMO CapitalFebruary 7, 2019 7:48 AM Regeneron (REGN) Tops Expectations Across Product Line, PT To $410 At BairdFebruary 7, 2019 6:29 AM Regeneron Pharma (REGN) PT Raised to $325 at BarclaysFebruary 7, 2019 4:59 AM